Centre Hospitalier Départemental Vendée

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate...

Assessment of infection prevention practices in office-based surgery: a multicentre regional audit

Abstract Background Office-based surgery (OBS) is increasingly used due to organizational constraints and perceived benefits. However, data on infection prevention and control (IPC) practices in OBS settings remain limited. This study aimed to assess the conditions in which OBS a...

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

In this ancillary study of the RELEVANCE phase III trial (NCT01650701), we performed the first direct intra-patient comparison of circulating tumor DNA (ctDNA)-based versus cellular t( BCL2 / JH ) translocation-based MRD at end of induction (EOI) in 278 patients with advanced FL,...

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN126...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...